American Well Corporation (AMWL) Earnings Call Transcript
May 5, 2026
Earnings Call Speaker Segments
Thanks, operator. Good evening, everybody. During the last 12 months, our attention went to the things that count the most: addressing distinct, pressing customer requirements; we provide a reliable, integrated platform, and the market is reacting. Elevance signed a three-year renewal. DHA went live worldwide. Our pipeline keeps expanding. CMS is progressively locking in telehealth flexibilities as permanent; during 2025, our losses came down by $100 million. We also achieved substantial growth in the share of revenue coming from subscriptions; we hold plenty of cash, carry no debt, and see an obvious route to reaching cash flow breakeven in Q4, with genuine confidence about multi-year growth after that. Amwell began 2026 with a single priority: pull our platform together and provide what payer and provider customers require most right now and going forward. The market opportunity is genuine and pressing. Payers face severe margin strain. Premiums aren't rising as quickly as the overall cost of care. Technology-enabled care and AI-powered clinical programs, especially, have become among the most essential levers available to payers. They assist with controlling costs; they assist with improving outcomes; they assist payers in competing for members and sponsors. This is no longer a matter of speculation; it has become a survival imperative. Adoption is still difficult. Even with robust demand, customers are finding things hard. Vendor sprawl places a genuine burden on them. Legacy tech stacks and internal silos drive up the expense of integrating point solutions. What comes of that? Member experiences end up fragmented, and there is very little visibility into what genuinely works. Customers find it hard to measure performance across their programs. Moving between programs or optimizing member attribution takes time, costs money, and causes pain. That is precisely the place where we come in. Amwell addresses this; we provide a trusted, established technology-enabled care infrastructure, an integrated digital stack enabling healthcare sponsors to function as their own system integrators. Customers white label and embed clinical programs their members require right inside their own digital front door. They manage navigation, they track results, and those results feed into what matters most to their business: reduced costs, improved outcomes, and a stronger market position; with Amwell, customers receive a single unified engagement and navigation platform. It lowers acquisition and retention costs. It pairs each patient with the program that works best according to client-defined rules. It seeks to provide unified analytics spanning every program so clients can identify what works, document outcomes, and pivot fast. Clients can modify service attribution by member, group, or cohort. They can bring in Amwell-native clinical programs, third-party programs, or their own preferred programs; that degree of control and agility is extremely valued and sought after. The Amwell platform was built for where AI is headed next. The industry is advancing quickly from generative AI to agentic AI. These are systems that don't merely generate content, they carry out tasks independently across complicated workflows. Our customers are getting ready for this change. The Amwell platform is positioned to serve as the governed environment in which these agents function safely, effectively, and at scale. We aren't positioning Amwell as an AI feature. We are the infrastructure layer where AI-powered care becomes operational and measurable. A crucial enabler of effective AI is data. Since our platform functions as shared infrastructure spanning every program, our goal is to keep one unified data structure—something no other company in this industry has. Prior to the start of care, we intend to pass pertinent member details along to whichever clinical programs the patient has chosen, allowing those programs to connect meaningfully right from the first interaction. Once care has been provided, we seek to gather and bring together outcomes data from every program; such data sharpens attribution, fuels personalization, and continually boosts the effectiveness of each AI-driven program. This shared data foundation could deliver a substantial and lasting competitive edge for us. We additionally possess strong validation at scale. Elevance Health, among the biggest payers nationwide, has extended its agreement with Amwell for another three years; that represents a robust endorsement of our platform and the worth we provide within one of the market's most advanced operating settings. We likewise hold strong validation when it comes to government. The August 2025 Military Health System contract extension placed our platform before 9.6 million military beneficiaries worldwide, linking deployed units both within and beyond combat zones to military hospitals; that degree of security, scale, and mission-critical dependability is precisely what other government entities, payer, and health system clients seek. The regulatory landscape now favors us. CMS has ensured telehealth access is permanent. Restrictions based on rural geography have been eliminated. Telehealth delivered from home has been extended through at least 2027. Virtual behavioral health now stands as a permanent Medicare component. Fresh reimbursement codes for advanced primary care management along with behavioral health integration are generating additional incentives to move care toward virtual and community-based settings. This amounts to a direct tailwind for our platform. We have likewise overhauled the way we operate. Together with bolstering our platform, we achieved meaningful operational gains, tighter focus, substantial organizational shifts, and more efficient methods of working. During 2025, we cut net loss and adjusted EBITDA losses by roughly $100 million. Subscription revenue climbed to 53% of total revenue, a recurring and stable income stream. The market is reacting. Renewals remain robust. Pipeline expansion is considerable. Our offering keeps connecting with current customers and new ones equally; we move into this next phase holding $182 million in cash, zero debt, an obvious route to cash flow breakeven in Q4 of this year, and an eye toward multi-year growth past that milestone. We possess a clear strategy, a mature and highly pertinent platform, an efficient operation, and financial stability that grants us the runway to execute. We are eager about what lies ahead. Now I would like to turn to Mark for a closer review of our performance. Mark?
Thank you, Ido, and hello everyone this afternoon. During this call, I'll begin by covering several key points from Q1, then take you through the financials thoroughly, and finish by sharing where we stand on guidance for the second quarter and the entire 2026 fiscal year. For the first quarter, our performance came in strong on revenue, gross margin, and adjusted EBITDA. This beat was fueled by robust visit volume growth in urgent care along with our clinical programs, plus ongoing expense control. What we achieved shows we keep moving forward on the road to profitability and gives us more conviction about where this business is headed. First quarter total revenue reached $54.9 million, a decline of roughly 18% compared with the same period last year. Subscription revenue came to $24.9 million, falling about 23% versus a year ago, mainly because of churn we had already told you about. On a positive note, renewals and retention came in above what we had budgeted for Q1, which gives us more assurance that our subscription base will remain stable moving forward. Revenue from Amwell Medical Group, or AMG, visits was $28.9 million, an increase of roughly 9% from the prior-year period. AMG paid visits came to about 382,000, a slight rise year-over-year, while revenue per visit landed near $76, roughly $5 more per visit than a year ago, which shows the rising contribution from our clinical programs and a wider mix shift toward care that is higher acuity and higher value. Virtual primary care kept up its robust growth trend, with visits climbing about 57% compared with last year, highlighting greater uptake of our VPC offering among the clients we serve. Platform visits in total came to 1 million, a drop of roughly 19% year-over-year, consistent with the portfolio adjustments we've described before. Gross profit was $28 million, yielding a gross margin of 51%, a decrease of about 180 basis points from 52.8% in the first quarter of 2025. In the near term, the revenue mix we currently have will probably produce a margin profile resembling what we just reported. We still expect our revenue mix to move toward higher margin SaaS products over time, which we think will drive margin improvement across the coming years as our scale grows. Total operating expenses came in at $45.4 million, roughly 31% lower than a year ago. Measured against revenue, operating expenses improved to 82.6% from 98.3% in Q1 of 2025, which shows the payoff from our transformation initiatives and our ongoing expense control. Adjusted EBITDA for Q1 was a loss of $3.1 million, versus a loss of $12.2 million in Q1 of 2025, which works out to a $9.1 million gain. Operating loss was $17.4 million, compared with $30.4 million in Q1 of 2025, an improvement of about 43% versus the prior year. Now on the balance sheet: we recorded cash burn of roughly $3.1 million, lower than the $19 million from last quarter. We closed the quarter holding $179 million in cash and investments, with no debt at all. Moving to guidance. For Q2 2026, our expectation is revenue between $48 million and $52 million, along with an adjusted EBITDA loss between -$4 million and -$2 million. This Q2 forecast accounts for typical seasonality in visit volumes and the ongoing reduction in subscription revenue caused by the churn we discussed earlier. Also, when looking at the entire year, we're keeping our revenue guidance where it was while revising what we expect for adjusted EBITDA. This new adjusted EBITDA figure takes into account how far we've come during the first quarter, along with what we anticipate carrying forward through 2026. Specifically, for the whole of 2026, we're now projecting revenue between $195 million and $205 million, with an adjusted EBITDA loss somewhere between $16 million and $12 million, which is an improvement over the loss of $24 million to $18 million we had previously guided. Because Q1 was so strong, we feel even more certain about our target of reaching positive cash flow from operations during this year's fourth quarter. To wrap up, the first quarter represented an encouraging beginning to the year. Momentum in visit volume, steady subscription revenue, and a more efficient cost structure all reinforce our belief that we're headed in the right direction. I'd like to express my gratitude to every member of the Amwell team for their commitment and effort. What we're seeing is a direct result of their work. With that, I'll hand things back over to Ido.
Thanks, Mark. The strides we've made give us real encouragement. Credit for that belongs to the incredible people here at Amwell. It's an honor to support better care for millions of patients—above all, for the servicemen and servicewomen in our armed forces and their loved ones worldwide. Amwell holds a key place in the effort to reshape healthcare. Our work carries real significance, and we're convinced its worth will keep growing from here. What we've achieved fills us with pride, and we genuinely look forward to what lies ahead; so with that, let's turn the call over to your questions. Operator, the floor is yours.
Hello, and thanks, everyone. Regarding the DHA partnership, could you refresh our memory or help clarify whether there are any dependencies tied to the wider MHS GENESIS program or to partners such as Leidos, and whether that ecosystem situation might affect any choice about renewal soon?
I think Ido might be experiencing some technical issues.
I'm sorry. I'm back, John. I apologize for this. Can you hear me now?
So basically, with a customer as vital as the DHA, our whole approach centers on meeting the quite particular and demanding standards they set. Having plenty of other participants alongside us is something we're grateful for, yet our priority stays fixed on ensuring that above all else, the customer comes first. Shifts are taking place across various domains, but what we deliver and how we're woven into the DHA's core framework does not change. From our vantage point, we hold a firm conviction that given how we've performed and the ties we've built, chances are good—and it's our hope—that we'll secure a renewal and keep serving this customer across many years, while acknowledging that among the other participants, some might or might not stick around in the same arrangement; we're reasonably sure and optimistic that we will, even so, that's never something to assume, and each day we put in the work to keep earning and warranting their confidence.
Understood. Thanks. For my follow-up, we discussed, maybe, a wider pipeline. I recall, maybe, a wider government pipeline that you brought up previously. Regarding the Rural Health Transformation Initiative, I was curious whether you perceive any possibilities, that this program might act as a diversification lever, compared to the wider government portfolio.
That's exactly right, John. Broadly speaking, since we concentrate our work on our single platform and related products, I noted during my prepared remark that people have tremendous clarity regarding the value we deliver and recognize the urgency in realizing that value that we think we offer rather uniquely. That holds for health system; it certainly holds strongly for commercial payers. Now that we have shown at very large scale, within a highly unique and demanding GovCloud environment, our capacity to function there, that isn't forgotten by government entities. As we see it, we definitely believe we will keep expanding in the commercial space, and also in the government space moving forward; we are attempting to submit RFPs for many of the opportunities you brought up in rural health; this is a lengthy process. We believe we are well-positioned, yet the outcome remains uncertain, and we'll simply need to wait, patiently, alongside everyone else. That isn't the sole opportunity in government that we are chasing. We're chasing additional opportunities too, and it's definitely part of the pipeline I discussed and Mark brought up as well.
Thanks.
Hello, I'm Corey, filling in for Stan Berenshteyn. I appreciate you taking my question. I have two things to ask. First, is there anything new regarding expanding what the existing DHA contract covers? Second, what is causing the quarter-over-quarter rise in deferred revenue? My understanding is that it went up by $7 million from one quarter to the next.
Corey, I'll handle the first one, and Mark will address the second portion. Thank you. Regarding the DHA, as I said before, our entire focus is on getting our agreement for the scope we currently have renewed; we are optimistic that will happen. When it comes to growing it further, particularly EverHealth, what we do know is that we previously rolled that out effectively and on a fairly large scale across various demonstrative regions. We know it, well, provided the value. Naturally, the choice belongs to the customer, and our hope is that they will broaden it at some stage, though right now we lack any concrete details about whether or when that might occur. Having said that, I'll pass it to Mark for your second question.
Right. That deferred revenue comes down entirely to when things land, driven by renewals from a few of our biggest customers — those happened during the first quarter this time, whereas a year earlier they landed at the close of the calendar year.
Great. Thank you.
You're welcome.
Appreciate you fielding our questions, and congratulations on everything achieved thus far. Earlier you mentioned the pipeline is expanding, and clearly retention along with renewals and subscribers came in above what was anticipated. That appears to give you confidence in how the model performs going forward. Perhaps we could dig deeper into that pipeline — could you share what the composition looks like, maybe from a dollar perspective, so we can gauge how much comes from health plans, health systems, and government? The reason I ask is that when examining 2025 revenues, Elevance Health is clearly your biggest customer, representing a fairly substantial share. DHA sits not too far behind. There's also meaningful concentration among the top 10. I'm just trying to figure out, looking ahead as we move through this stretch and consider where growth will originate, whether you could help us see which opportunities seem simplest to pursue and how the pipeline mirrors that. Thanks.
Of course, Charles, thanks for being with us. Great to hear from you. Regarding the pipeline, like we said before, it's substantial and quite unlike prior years. Let me describe it somewhat qualitatively. The thrilling part is that our new offering, the Amwell Platform, connects extremely well throughout the market. This instrument enables us not just to earn subscription revenue, but additionally to expand the associated clinical services — Amwell plus non-Amwell offerings — from which we likewise bring in revenue while doing so. I noted before that although this technology and these offerings matter to health systems, payers, and government bodies universally, my strong conviction is that the sharpest requirement is clearly among large payers; they unmistakably require infrastructure of this kind. When that occurs, a couple of outcomes follow. First, we gain some new logos, yet far more crucially, when they roll out our platform, it feeds same-store growth. As it grows increasingly effective at generating engagement among additional members, and it's designed to boost per-user usage of the clinical programs I referenced, motivating sponsors to keep funding both engagement and coverage as we can show and verify outcomes — financial and clinical — which likewise propel success during open enrollment and market expansion. For us, it feels quite invigorating to witness a product mix that once consisted of numerous products spanning huge markets consolidate into basically a single platform plus associated services, yet still produce very robust pipeline growth and strong enthusiasm among current and prospective customers.
Could you possibly give us some sense of how that expansion might appear? When you say pipeline growth, are we talking about double digits compared with a year ago? Is there anything at all you're able to tell us regarding the outlook for that growth?
Charles, let me step in here and offer this: compared with where it stood last year, the pipeline now stands at several times that level, which means it would land nearer triple digit thanks to the opportunities Ido spoke about. Once more, this largely aligns with what we expect to be mainly elements of government opportunities.
All right. Perhaps only one additional item, if that's okay. I believe, regarding an earlier question, an update about DHA. Could you remind everyone about the schedule for when a decision should arrive concerning the renewal? Also remind us, if by some chance no renewal happens, what alternative does the government have, since it's the DoD? Because from what I understand, they truly lack one. And finally, could you remind us what growth possibilities exist alongside this renewal? Would they arrive jointly, or would those amount to two distinct decisions? Thank you.
Charles, regarding the renewal, our view is that it should be quite simple; our expectation is that it wraps up by the quarter's close, the beginning of Q3, possibly July; we likewise expect that the chance for expansion comes following the original renewal. As Ido mentioned before, whether it's a direct contract, whether we keep collaborating with our Leidos partners, no matter who ultimately becomes the contracting party, we are quite confident that this renewal will begin during the period I just described.
Excellent. I'm grateful for that. Many thanks, everyone.
You're welcome.
You're welcome.
Thank you.
Thank you. I appreciate you fielding my questions. To start, I'd like to ask about visit volume during the quarter, which came in near $1.1 million. How does that compare with what you had anticipated internally, and what is behind the full-year guidance range of $1.3 million-$1.37 million? I ask because a number of providers have described a soft volume pattern. They pointed to a mild flu season and some weather-related disruption, which could have worked in your favor. I'm just curious about the puts and takes you encountered in Q1 and how you view the trends for the remainder of the year.
Hi, Jailendra; this is Mark. The trends came in positive on both fronts when it comes to premium priced visits — meaning those tied to more expensive care, particularly the clinical programs and virtual primary care, rather than urgent care, which had generated the bulk of our revenue-producing visits in earlier periods. In addition, volume grew at a nice high -single-digit rate; we didn't run into the softness that others might have described to you. In fact, a favorable seasonal lift carried us through to the quarter's close. At this point we're, as you'd expect, seeing the usual seasonality take hold; that lift was a pleasant surprise. I believe it was helped by the fact that additional ASO clients are now taking part in the offerings we've rolled out. The direction is favorable, and we anticipate that continuing across the year.
Thanks. For my second question — you mentioned quite a few significant renewals along with a robust pipeline. In your conversations with clients these days, how frequently does AI come up? Does that change depending on whether you're speaking with a health plan rather than health systems? And on that note, whenever clients assess what you can do with AI, do they agree to pay for it as a separate item, or do they feel it ought to be included within the platform and price they already have? How are those discussions shifting?
Hello, Jailendra. Excellent question. The answer, in essence, is somewhat complicated. When a customer purchases the platform, certain AI features we provide tie directly into areas such as the consumer experience, making navigation more streamlined, delivering advanced analytics, and similar items. What's interesting is that not every one of our customers is prepared to embrace those modules. A number of them are in fact quite wary of those modules and instead concentrate on the recurring, stable, proven portions of the platform as what matters most to them. That said, every single one of our customers, with no exception, is keen and prepared to trial AI-driven clinical programs on the platform. The explanation is that we designed the platform so that integration happens very quickly, while deintegration and replacement happen even more quickly, all without altering much, such as the consumer experience or the analytics. There's broad acknowledgment that AI clinical programs are required in order to attain and enhance clinical and financial outcomes, and they demonstrate that; yet that doesn't have to show up in the risks tied to the platform itself, but instead relates more to the various programs that people trial. Although we have a solid amount of AI within our own offering, which we roll out to customers who are prepared to gain from it, the greatest value we deliver is the safe, reproducible, scalable manner in which our customers can trial various options. The majority of those are AI driven, not always for an entire cohort, but instead for particular ASOs compared with others and so forth, and then truly handle risk while retaining access to all the possibilities that such innovations deliver to them.
Great, thank you very much.
Could you expand a bit on the Defense Health Agency contract? I believe there was a piece in it, mental health I think, that lapsed and could potentially be brought back later and grow. What's the yearly dollar figure for that, if you don't mind?
Hello, David. The precise dollar figure isn't something we can address, though our expectation is that it would account for more than 15%-20% of the platform's overall value as it stands now. That estimate comes from what we saw at the start of 2025, when the DHA was making active use of those services. We're deeply involved in conversations about bringing those services back. That said, our view is it will probably happen following the base services' renewal taking effect earlier this summer.
Could you describe what those services actually involve? Are we talking about mental health? Is that right? Given the sort of duties and responsibilities those in the military carry out, I'd imagine nothing is more needed than mental health services for them. It seems to me the federal government would be quite willing to provide any assistance it can to support, you know, the men and women serving in uniform.
Hello, David. Ido here. Clearly, I couldn't agree more with what you said, and we remain quite optimistic that it will come about. Here's how things stand: We feel tremendous gratitude for being positioned as the backbone and infrastructure supporting technology-enabled care for the U.S. military. This concerns the essential link between any person in this remarkable family and their physicians, no matter where those physicians happen to be. That's Amwell. Beyond that, one clinical program that clearly works as a native fit, completely embedded within what we offer, is our automated behavioral health program, and a key advantage of it is enabling a small number of therapies to reach vastly more patients; that's an enormous issue. Behavioral health overall suffers from a massive imbalance between supply and demand, and that extends to a setting such as this one. This isn't hypothetical. I mean, we've tested it in this setting; we brought it in, and it functions, and it's required. For reasons of their own, the customer chose to postpone that rollout once we'd demonstrated it performs well and is fully integrated, and that's completely okay. If the client ever opts to bring it back, things could move extremely fast. We think it will prove extremely beneficial, and it certainly is logical. Such choices rest entirely with the customer, not with us. We're aware it performed very effectively, not just in settings like the DHA, but also, for instance, with the National Health Service, the NHS, in the U.K., where research showed we were able to drastically alter the proportion of therapists to patients. That's clearly a fantastic outcome, both in terms of expense, but even more so in terms of speeding up access, which is such a source of frustration for everyone.
Looking ahead to 2027, should we anticipate that revenue will increase compared with the prior year? I realize some churn has taken place. Any additional detail you can share regarding the churn that's already happened would help. What caused it? Could it be just one client or two? Do you anticipate revenue rising in 2027 versus 2026?
Absolutely. Churn during 2026 has not been material. In any competitive-market business, we'd constantly anticipate churn in the low single digits. Our expectations regarding revenue growth are substantial. Even at the close of last year, I referenced this, noting that should even a portion of our pipeline convert during this year, we anticipate considerable revenue gains in 2027, driven by those newly secured government contracts.
Alright, just one final quick item. Mark, amazing work on bringing a lot of those expenses to heel. So, would you say you're basically finished, or is there additional incremental annualized cost you can extract from the business? Good job, incidentally.
Well, I'm grateful for that. Naturally, I'm also speaking for every one of my co-workers, since, as you're aware, it takes teams — really an entire village — to reach that point. Folks at this company have accomplished a great deal more with significantly less throughout the last 18 months. All of us feel quite good about our current position. Everyone recognizes the task isn't done; we've got the coming 2 quarters to make sure we finish some of the programs we've put money into across the previous few quarters. There is a step down in expenses, meaning a reduced operating cost base as we exit the third quarter; we're making solid progress. You can likely sense how hopeful and thrilled we are to hit that milestone, yet we're equally thrilled about what we think will be substantial growth in the year ahead.
All right, many thanks. I’ll rejoin the line.
Thanks.
Thanks, Ari. I want to thank all of you for being here. We genuinely value the support you've given Amwell over many years, and we're eager to speak with each of you before long. Stay well.
We appreciate you joining us for today's call, and with that, the program has come to an end. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Well Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to American Well Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.